We can’t make true progress on unmet medical needs unless we understand what the patients themselves think they need or say is missing from their treatment options.

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare ...

French immunotherapy company OSE Immunotherapeutics has appointed Dr Sonya Montgomery as chief development officer. She will ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.

We’ll hear from speakers representing Syneos Health, Flagship Pioneering, and IPSEN on pharma dealmakers’ 2025 intentions, ...

Stakeholders from the healthcare sector have strong expectations for reforms aimed at tackling long-standing challenges and ...

Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's ...

Pharmaceutical and hospital sector executives are requesting higher public healthcare spending, R&D incentives, and tax ...

Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025.

Tiwari, who serves as Senior Vice President at the world’s top asset management firm, emphasized the transformative potential ...